Mr Wood was removed from the Register in 2018 after being convicted of posessing indecent images of children and made subject to a Sexual Harm Prevention Order for five years.
Mr Wood first applied to rejoin the Register in 2020 but his application was rejected.
At the outset of his second application last month, Mr Wood’s counsel argued that he is professionally competent to be restored, that he had strong mitigation for his offending, that he had consistently and repeatedly expressed and demonstrated profound remorse, that he posed a low risk of re-offending, that he had proactively engaged with the Probation Service and voluntary counselling to gain further insight into his offending, and that he had completed his community sentence and was no longer subject to any of the court orders arising from his conviction.
The Committee then weighed up whether Mr Wood had accepted its original findings in 2018, the seriousness of the offences, whether he demonstrated insight, protection of the public and the public interest, the future welfare of animals should he be restored to the Register, the length of time off the Register, Mr Wood's conduct since he was removed and evidence that he had kept up-to-date with veterinary knowledge, skills and practice.
Dr Kathryn Peaty MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee is satisfied that Mr Wood has done everything required of him in order to be able to satisfy the Committee that he is fit to be restored to the Register.
“At the last application in June 2020, he was unsuccessful largely because of the outstanding ancillary Court Orders that did not conclude until early 2023. Those Orders have now concluded
“He has shown significant insight into his offending behaviour. He has been proactive in his rehabilitation and taken significant steps to ensure there would be no repetition.
“He has a small, but strong, network of people around him who appear to genuinely care about him and support him. He has worked hard at maintaining his skills and knowledge, in so far as he has been able to in light of not being able to practise as a veterinary surgeon.
“He is thoughtful and realistic about his prospects going forward. His responses to questions about addiction were appropriate and persuasive. He has expressed genuine remorse and there is, in the Committee’s view, a public interest in allowing him to be restored to the Register.”
www.rcvs.org.uk/disciplinary
According to the charity, FIP, which is one of a number of chronic viral infections of cats that resemble those in people, is estimated to kill up to 1.4% of cats around the world.
The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.
Among the most promising treatments against emerging viruses in humans is 'GS-5734', one of the small-molecule antivirals targeting specific proteins involved in RNA virus replication.
In studies, it has proven effective in preventing Ebola in rhesus monkeys and inhibiting coronaviruses both in tissue culture and in mouse infection models.
It was these findings that brought it to the attention of a team of veterinary researchers in the USA, led by Professor Niels Pedersen of the University of California, Davis.
Their own initial studies involving experimental FIP showed that the less chemically complex 'GS-441524', the parent nucleoside of GS-5734, was highly effective, opening the way for a field trial in cats with naturally occurring FIP, the results of which are published in this week's JFMS2.
Thirty-one cats, ranging in age from 3–73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanised due to their severe disease.
For these 26 cats, the clinical response was dramatic: fever usually resolved within 12–36 h, concurrent with a marked improvement in appetite, activity levels and weight gain.
In cats with the more common effusive or ‘wet’ form of FIP, abdominal effusions rapidly disappeared, starting at around 10–14 days after commencing treatment.
Encouragingly, and somewhat unexpectedly, cats with non-effusive (‘dry’) FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.
Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.
Previously the prospects for cats with FIP were bleak. In a review paper on FIP published in JFMS a decade ago, Professor Pedersen stated: "no treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of their disease in days, weeks or months."1
Now, as he approaches the end of his professional career, Professor Pedersen is considerably more optimistic: "FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP."
However, he cautioned: "It must be emphasised that the field trial we report was for proof-of-concept and the results cannot be immediately translated into commercially available products.
"Unfortunately, the real hope provided by these initial trials has increased, and not decreased, the desperation of owners to seek out these new drugs on the black market. As eventful as these discoveries may be, there is still much more about FIP to discover.
"I would like to thank all of the people, organizations and owners who have assisted in my research over this half century and leave remaining questions and associated discoveries for my fellow FIP researchers."
Reference
Photo: Bubba, one of the study cats, in recovery. Courtesy Adel Gastle
Cladaxxa is a combined amoxicillin/clavulanic antibiotic, which Krka says is bioequivalent to the market reference product1,2,3,4.
The new product is available in three strengths of flavoured tablet, with the 200/50 mg formulation also licensed for cats.
Cladaxxa is presented in blister packaging to protect the clavulanic acid, which is highly sensitive to moisture.
The tablets are ready-scored to help with accurate dosing and halved tablets can be returned to the protective blister packaging to be used within the following 24 hours.
Cladaxxa comes in packs of 60 or 100 tablets.
Krka’s National Sales Manager Will Ridgway, said: "Treating bacterial infections is an important everyday task for vets in practice.
"Cladaxxa is a great example of Krka using its expertise in end to end product design to deliver efficacy and value to our customers.”
References
The test, which enables the rapid identification of cattle infected with Mycobacteria, was first developed by Dr Swift as part of his PhD studies at the University of Nottingham. Since joining the RVC, he has continued to evolve the technology working alongside academics at his former university.
Dr Swift and Dr Rees were presented with the award by HRH the Princess Royal.
The Royal Dairy Innovation Award recognises research and development in the field of dairy farming and is awarded for the most practical, relevant product or service which is, or likely to be the most significant innovation for the future.
The RVC says the test is able to detect mycobacteria in the blood and milk of cattle within six hours using a bacteriophage-based technique. As a result, cattle affected by Mycobacterium bovis, the bacteria that causes bovine TB, can be diagnosed for the disease more quickly, allowing for more effective disease management in herds.
Additionally, the test has been used to effectively detect Johne’s Disease – another endemic illness that affects dairy cattle – in new born calves for the first time. By being able to catch the disease at an early stage, this test can help further with controlling infections in dairy herds.
The test is now licenced to spin-out company, PBD Biotech Ltd and marketed as Actiphage. It can also be used as a highly sensitive quality assurance test in milk and dairy products.
Dr Swift, who is a Research Fellow in antimicrobial resistance, said: "It is really exciting to be recognised with this award. Translating technology from the bench to be used in real-world scenarios is a great thing and really shows the impact of our research. Hopefully this will help manage two extremely difficult diseases in the UK and worldwide."
Photo: Benjamin Swift (RVC), Dr Cath Rees (University of Nottingham), Princess Anne and Dr Berwyn Clarke (PBD Biotech).
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)
The Disciplinary Committee, chaired by Mr Stuart Drummond, considered six charges against Dr Gunn.
The first charge alleged that, early in 2018, Dr Gunn failed to provide appropriate and adequate care to the dog. In particular, having removed a mass from the right thorax, he undertook an excess number of surgical procedures, including under general anaesthetic, within a 13 day period; performed these procedures without offering alternative treatments or discussing referral with the owners; failed to recognise infected wounds; and administered an antibiotic when the dog was infected with MRSA and E-coli.
The second charge alleged that Dr Gunn failed to communicate adequately, openly and honestly with the owners of the terrier on multiple occasions between 16 January and 3 February 2018. This included but was not limited to: failing to provide the owners with an estimation of fees; failing to inform them in advance of the procedures performed; failing to inform them of options for treatment; and failing to inform them that the terrier had an infection when he knew or ought to have known that she did.
The third charge alleged that Dr Gunn failed to obtain informed consent in relation to the further procedures performed on the terrier in charge one.
The fourth charge alleged that Dr Gunn failed to maintain adequate clinical records in relation to the management of the dog, and that he failed to record the prescription and administration of drugs to treat the terrier.
The fifth charge alleged that Dr Gunn indicated to the owners that euthanasia was the most appropriate treatment option and/or that there were no other realistic treatment options, when this was not the case and when he ought to have known this was not the case.
The sixth charge alleged that, during the course of a referral of the terrier to another practice, Dr Gunn failed to provide an adequate history of his management of the dog and that he informed the practice that the owners had no finances when this was not true, amounting to an incomplete account of his dealings with the owners and to a breach of their confidence.
At the outset of the hearing the respondent admitted to a number of the allegations within the main six charges, which were found proved by the Committee.
Of the charges not admitted to, a number were found proved and the Committee then went on to consider whether or not Dr Gunn’s conduct amounted to serious professional misconduct.
In considering the aggravating factors, the Committee took into account that the dog’s suffering was prolonged because of the persistence of Dr Gunn in pursuing a single ineffective treatment approach.
With regards to mitigating factors, the Committee found that Dr Gunn was remorseful as to his actions, that there was no financial motivation on the part of Dr Gunn in respect of his treatment of the terrier, and that there is a low risk of repetition because Dr Gunn has sought to learn from this experience. A number of relevant and high-quality testimonials were also provided by colleagues and many satisfied owners on behalf of Dr Gunn.
Considering both the aggravating and mitigating factors, the Committee was satisfied that Dr Gunn’s conduct fell far below the standard expected of a registered veterinary surgeon for a number of the charges.
The Committee then considered what sanction to impose on Dr Gunn. The Committee was satisfied that the misconduct found proved was in relation to the treatment of one dog only and therefore it was at the lower end of the spectrum. However, the conduct took place over a prolonged period of two weeks which in the Committee’s view required a sanction. In such circumstances, and with the significant mitigation, the Committee decided that the appropriate and proportionate sanction was to reprimand Dr Gunn and to warn him about his future conduct.
Speaking on behalf of the Committee, Mr Stuart Drummond said: "The Committee concluded that the effect of a reprimand alongside the Committee’s findings on disgraceful conduct in a professional respect was a sufficient and proportionate sanction. The Committee found Dr Gunn to have developed sufficient insight into his failings and it was satisfied that the disciplinary process had been a salutary experience and that he is very unlikely to pose a risk to animals in the future or to contravene professional standards.
"The Committee decided that a warning as to future conduct was necessary to reduce the risk of any repetition of any similar conduct for Dr Gunn in the future. It therefore concluded that the sanction of a reprimand and warning would be a sufficient in the circumstances of this case having taking into consideration all the powerful personal mitigation."
The complete list of charges and the Committee’s full facts and findings can be found at www.rcvs.org.uk/disciplinary
Merial is to launch Frontect (fipronil and permethrin), a spot-on solution for dogs with dual action: treatment and prevention of fleas and ticks, and repellency against ticks, sandflies, biting flies and mosquitoes.
According to the company, Frontect kills fleas within an hour for the first week and within six hours for four weeks1. The repellent (anti-feeding) effect of Frontect prevents parasites from taking a 'blood meal' and as a result, Merial says vets and pet owners can feel confident that they are helping to protect dogs from the vectors of severe canine diseases - including leishmaniosis, dirofilariosis, babesiosis, anaplasmosis, ehrlichiosis and borreliosis - whether travelling within the UK or abroad.
Lynda Maris, Brand Manager for Frontect said: “We are delighted to expand our Merial V-Line vet exclusive parasiticide portfolio with the addition of Frontect. Frontect both kills and repels parasites to provide visible results and help deliver client satisfaction. Frontect is ideal for active, outdoor dogs and travelling dogs at risk of exposure to ticks and vector borne diseases.”
Frontect is administered topically, on the neck and between the shoulder blades of the dog. It will be available in five different weight ranges to suit all dogs from the beginning of May 2015.
For the study, 309 university students were randomly assigned to one of three four-week stress prevention programs featuring varying levels of exposure to animal-assisted activities and evidenced-based stress management content.
The research found that students who were considered at a higher risk of poor academic performance saw a significant boost in executive function including improvements in attention, memory, self-regulation and improved cognitive function when they received exclusive exposure to interaction with the dogs.
This improvement was not seen in students who participated in a more traditional stress management learning program using lectures containing information about stress management or sessions that combined such information with lower levels of animal interaction.
Lead study investigator, Associate Professor Patricia Pendry, from Washington State University said:"Academic stress and associated negative impact on student performance is a significant issue for universities today and something we need to better address.
"While more traditional learning programs continue to play a role, the results of the study are exciting as they indicate this type of intervention can be a positive stress management tool especially for students who are at-risk of poor academic performance.
“We know from previous research the positive effects of animal visitation programs on the mood3 of college students – and even recently discovered their positive effect on stress hormone levels4. However, this is the first study to demonstrate that more frequent and regular inclusion of dogs can positively affect aspects of cognitive functioning that may be more difficult to change with existing interventions."
Study co-author and expert in Human-Animal Interaction expert Professor Nancy Gee said: "This study was informed by previous research and reinforces the growing body of evidence showing the benefits of pets for people in many different contexts and for at-risk groups.
"This type of animal-assisted stress reduction program is both easy to implement and low cost – offering a fantastic way for universities to support their students. After participating, participants feel calmer and more socially supported and this leads to an improvement in mental health and cognition.
"My hope is that evidence-based interventions which are already gaining popularity can become common practice in educational settings."
References:
According to the AHT, glaucoma affects more than a thousand dogs across the UK. Now Border Collie breeders will be able to use this test to reduce the risk of producing glaucoma-affected puppies, whilst maintaining genetic diversity.
The work that resulted in the new test began at the Roslin Institute in Edinburgh, where scientists found a variant in a gene called OLFML3 reported to be associated with severe goniodysgenesis and glaucoma in Border Collies.
On reading this research, the AHT’s canine genetics team, which has an ongoing research programme looking at canine glaucoma, began to look at how a DNA test could be offered based on the mutation.
Hattie Wright, Vets4Pets Research Assistant at the AHT, genotyped a large cohort of Border Collies for the mutation, in order to obtain an accurate measure of the association between the mutation and goniodysgenesis and glaucoma in the Border Collie. These dogs all had their eyes examined, and their DNA collected, by veterinary ophthalmologist James Oliver.
The charity’s findings from this validation process replicated the findings of the Roslin Institute, so the AHT has been able to develop and launch a DNA test based on the reported OLFML3 mutation.
Dr Cathryn Mellersh, Head of Canine Genetics at the Animal Health Trust, said: "We’re delighted to offer this test to Border Collie breeders and hope in time, through its use, we can lessen the prevalence of this disease in this lovely breed.
"Our research has found that the mutation is only associated with glaucoma in Border Collies, so we will publish our data at the earliest opportunity, in the hope that other commercial DNA testing providers will not be tempted to make the DNA test available to breeds other than the Border Collie."
For more information, visit: www.ahtdnatesting.co.uk
The new drug represents the fruit of 8 years of product development and more than 11 proprietary studies performed by Ceva R&D teams.
Marie Boutot, development project leader said: "Isemid is an original drug developed by Ceva, and was the subject of full pivotal efficacy and safety studies."
Ceva says the new drug has been recognised by the European Medicines Agency as a "2018 Innovation, advancing animal health".
Isemid is presented as pork-flavoured, scored tablets in three strengths: 1, 2 and 4 mg. They can be administered orally once daily, with or without food. The company's research showed a 98% owner compliance (compared to 92% for furosemide, p<0.05) and 80% voluntary acceptance.
Emilie Guillot, DVM, Ceva Technical Manager for Cardiology said: "With Isemid, we seek to help veterinarians in their goal to improve survival of dogs with heart failure.
"But above all, thanks to its potent action and long half-life which allow once-daily dosing, we hope to ease owner compliance."
Scientific communications with data on Isemid were presented at the American College of Veterinary Internal Medicine forum in Phoenix in June and will be held at the European College of Veterinary Internal Medicine congress in Milan in September.
Having listened to the recording, it strikes me that the Veterinary Record has misinterpreted Mr Innes, and the danger is that his perfectly valid point will now get drowned in a sea of outrage.
What Mr Innes actually said was: "I think it is time to start creating a more fulfilling, more rewarding career for our nurses, and I think that the Americans are showing us the way. They have vet techs and I think that we can do that; I think that isn't the, necessarily the answer, but one it will create a much more rewarding career for veterinary nurses and also some of the reason that vets leave is because they don't like the mundane stuff, so let's give the mundane stuff to nurses.
Considering the overall context of what he said, it is glaringly obvious Mr Innes champions the idea of giving nurses a more rewarding role. So the idea that he was saying: 'Let's give the shit jobs to nurses' is frankly ludicrous.
It is obvious that what he actually meant was 'Let's give some of the stuff that vets find mundane to nurses.' He just didn't express it as well as he might have done.
Mundanity is subjective. What is mundane for a vet is not necessarily mundane for a veterinary nurse, particularly one who has been relegated to sweeping floors for any length of time.
Mr Innes has come in for quite a lot of flack for some of his comments recently. I'm not sure about the other stuff, but on this, he is clearly not guilty.
You can agree or disagree with his view that nurses could be given greater responsibility and vets could delegate some of the tasks they find mundane.
But it would be a great shame if his point got drowned in a sea of outrage over semantics.
Elanco Animal Health has launched AviPro Salmonella Duo, a new live vaccine which provides simultaneous protection against S Enteritidis and S Typhimurium in poultry.
Jessica Cross, Elanco's poultry veterinary consultant said: "AviPro Salmonella Duo is the first vaccine to have both Salmonella strains in the same vial and also the first to be licensed for turkeys and ducks as well as chickens."
Unlike inactivated vaccines which are administered by injection, AviPro Salmonella Duo is administered in the drinking water. Elanco says this offers producers significant advantages since the oral route allows mass administration without stressing the birds, saving labour and improving welfare. A three-dose programme provides immunity throughout lay.
The new vaccine also provides an eight-week increase in the period of immunity over its predecessor, to 62 and 68 weeks of age for S Typhimurium and S Enteritidis respectively.
Jessica said: "This development represents the third generation of vaccines, moving on from the early dead vaccines, individual live vaccines to the bivalent product. Producers will welcome the simplified administration it offers."
The online academy offers a range of materials to help veterinary surgeons, nurses and receptionists further their knowledge of obesity as a disease, support the running of weight clinics and ultimately help reduce the number of overweight cats and dogs.
The academy includes Weight Management Online, an interactive course which is designed to improve the management of obesity in practice. The course offers eight hours of CPD and additional support from Royal Canin's dedicated Weight Management Team via an online forum.
The course modules are: Obesity is a disease; Body Condition Scoring; Feeding for weight loss diets; Communicating the positives of weight loss; Running a weight loss clinic; and Success is a team effort.
Each module contains additional downloadable reading material and/or learning tools.
Courses run from 11th September to 1st October 2017 and 13th November to 3rd December, with three weeks given to complete the six modules.
Louise Brennan, a Weight Management Specialist at Royal Canin, said: "The prevalence of pet obesity is increasing in the UK, with at least 59% of all dogs and 39% of all cats overweight or obese¹. We have recognised the need to provide further education to help veterinary staff understand the seriousness of the disease and how to communicate this to owners."
Veterinary surgeons and RVNs that complete Weight Management Online within a three week time frame will be invited to complete the second stage, allowing them to become a Royal Canin Weight Management Counsellor.
For more information, contact your Royal Canin Veterinary Business Manager.
VetSurgeon Reactions now gives members a quick and easy way to say 'thank you' for sharing something in the forums or the photo/video galleries, and, in the future, for VetSurgeon.org itself to reward those members whose contributions are most appreciated by the community.
In addition to saying 'thank you', members can also say they 'agree' or 'disagree' with the content of a post, a far more precise expression than the previous rating system, in which 'one star' which could be interpreted as meaning almost anything.
VetSurgeon Reactions also give you a quick and easy measure of how much a contributor has been thanked, agreed with or disagreed with by other members.
With a number of new features introduced over the last year, VetSurgeon.org now offers far more compelling reasons to hold clinical discussions in its forums, rather than other other social media platforms:
VetSurgeon Profiles are visible to all logged in members, so you can see the professional credentials of the person who posted advice or opinion.
VetSurgeon 'Claim CPD' allows you to record time spent in clinical discussions, and claim a downloadable VetSurgeon CPD certificate towards your annual CPD requirement.
VetSurgeon forum discussions are far, far easier to follow and refer back to than Facebook discussion threads, which are more transient in nature.
VetSurgeon.org Co-Editor Liz Barton MRCVS said: "I think that the combination of these things mean that whilst Facebook groups can offer a great environment for chat about all sorts of professional issues, VetSurgeon.org really excels when it comes to accountable, good quality clinical discussion you can follow and refer back to.
VetSurgeon Editor Arlo Guthrie added: "As for 'thank you', I don’t know why I didn’t think of it years ago. 'Thank you' is something missing from almost every other social media platform I’ve ever seen, and yet it’s SUCH an important courtesy.
"So, remember, if you see something on VetSurgeon posted by another member which you found helpful, don’t forget to hit the 'thank you' button. If they’ve had one of those days when every client seems utterly thankless, some appreciation from their peers might make a lousy day bearable."
Derbyshire surgeon Victoria Lilley BVSc CertSAM MRCVS has launched a petition calling on the RCVS to abandon its plans to remove Certificate and Diploma holders' post nominals from the RCVS Register at www.rcvs.org.uk.
Under the current plan, which followed a consultation in 2011 and a submission to Council in 2012, the College will only distinguish the new "Advanced Practitioners" and "RCVS Recognised Specialists" in the Register from some time after the autumn. Vets with old-style RCVS Certificates can apply for "Advanced Practitioner" status but must complete module A of the CertAVP or 100 hours of equivalent CPD and pay £50 to apply, plus £110 per year to maintain the status.
Victoria said: "I want to spread the word that this is happening, as I don't feel the RCVS has publicised it well enough. I did my certificate in practice, it was a lot of hard work and I feel that the RCVS removing my CertSAM post-nominals from the register undermines this. Whilst I acknowledge that I could apply for "Advanced Practitioner" status, I strongly feel that spending a large proportion of my CPD time and budget learning about ethics and public safety is not going to help me improve my small animal medicine knowledge or skills. I also don't feel that I should be penalised by having to pay to be an "Advanced Practitioner" when the Royal College should be supportive of vets who undertake further study. My biggest objection is to post-nominals being removed from the register, which I feel is very unfair."
Speaking at the RCVS's online Question Time on thewebinarvet.com, RCVS Treasurer and Vice-President-elect Dr Bradley Viner said: "To clarify the situation with the Register: the Register no longer goes out to members routinely as a printed document. It is now primarily online, and in line with other regulators such as the GMC, the only information that is in the official part of Register is whether that person is a Member or a Fellow of the Royal College of Veterinary Surgeons and their registrable qualifications, in other words the primary qualification they achieved which entitled them to become a Member or Fellow of the Royal College.
"But we are certainly not going to be inhibiting people from using their post-nominals freely. They can use any of the post-nominals that they have achieved as long as they are not misleading.
"But I think there is confusion between a qualification and a status. A qualification is something that you obtain and you've got for life, and of course the old style Certificate is one of those, the new RCVS CertAVP is another. A status is something that a qualification within our context might enable you to attain, but it is something that has to be maintained.
"So what is going to be happening, hopefully from autumn this year, is that in line with the recommendations of the Specialisation Working Party, [there will be] an extra tier. So there will be Practitioners, there will be Advanced Practitioners and there will be RCVS Recognised Specialists, and there will be lists of those available via the Royal College. An Advanced Practitioner will be somebody who has a relevant qualification in the area of their advanced practice, and that may well be an old-style Certificate, certainly the CertAVP but there are also other qualifications which can also be relevant and used for that purpose. But they also have to prove that they are working actively in that area of practice, and they have an advanced requirement for CPD.
"Now in the case of old style RCVS Certificate holders, that qualification will be in line with the qualification they require to be listed as an Advanced Practitioner, but within the first three years they will have to show that they have either done the RCVS A module which is part of the new RCVS Certificate, or have done work that is equivalent to that in various areas such as communications, teamworking and personal and professional development, because we think from a Royal College point of view that it is really important that those areas are included within the Advanced Practitioner Status."
To sign the petition, visit: http://www.change.org/en-GB/petitions/royal-college-of-veterinary-surgeons-keep-post-graduate-qualifications-on-the-rcvs-register?recruiter=89624244&utm_campaign=mailto_link&utm_medium=email&utm_source=share_petition
Lead surgeon at Roundhouse, Ross Allan (pictured right), an RCVS Advanced Practitioner in Small Animal Surgery, said: "We know many practitioners and clients have been frustrated by the difficulties in availability of TPLO in Scotland and we wanted to change that.
"As with our other Roundhouse Referral offerings, we have done away with long waiting lists, unpredictable pricing, and challenges in clinical continuity. We know that in doing so we will revolutionise access to this service and the experience of its users.
"Our TPLO service offers excellent value and quality – we have invested heavily in the very best DePuy Synthes TPLO plates and implants and, together with our hospital status, standards and track record, we are offering a premier TPLO service in Scotland: a TPLO with a recovery that is as reliable and predictable as our Fixed Price!"
The fixed prices for a TPLO are £3000 for dogs under 40kg and £3100 for dogs over 40kg.
The price includes the consultation, diagnostic X-rays/assessment, pre-surgical blood samples, hospitalisation, anaesthesia, surgery (including implants), follow up consultation and follow up X-rays.
Ross added: "We don’t expect anything to go wrong, but should we need to revise our surgery we would do so at no additional cost to the client – that’s our Fixed-Price Fix!"
To make an enquiry, or refer a patient for a Fixed Price Fix TPLO contact Roundhouse Referrals at 0141 649 1316 www.rhr.vet
Online veterinary pharmacy Vet-Medic has announced the results of a survey which showed that veterinary practices are charging pet owners 100% more than online pharmacies for well-known drugs.
The survey compared the prices charged by veterinary practices, online pharmacies, pet superstores, supermarkets and veterinary medicine suppliers. Amongst other things, it found a six-pack of Frontline for cats available online for £16.33, vs £38.95 in practice. Optimmune was available for £23.86, compared to a practice in North London selling it for £59.81.
Andrew Evans, Managing Director of Vet-Medic said: "This research offers huge insight into the pricing structures of pet medication. When we commissioned the research to help us keep our own pricing competitive, we made an assumption that online shopping should come out cheaper but were staggered by how much."
He added: "Not many pet owners are aware that vets are obliged, in most circumstances, to provide them with a prescription when asked. How and where the prescription medicine is purchased is actually the owners' choice."
The BVA responded to the survey yesterday. President-Elect Harvey Locke said: "The Vet-Medic claim that veterinary practices are over-inflating the price of veterinary medicines is an unfair accusation.
"Veterinary practices will mark up the cost of the medicines they supply in order to cover the costs of keeping and dispensing them. This includes having trained staff available, buying the necessary equipment, and storage facilities that are governed by strict rules, and covering the cost of wasted medicines that have a short shelf life.
"Online pharmacies have similar overheads but are able to buy in much larger quantities than the average veterinary practice due to the much higher volumes sold. Many of the internet prices revealed in the survey are around the same cost as veterinary practices can buy the medicines from wholesalers suggesting that some of the internet companies are sourcing cheaper drugs abroad.
"As with many products buying online can be cheaper and consumers have a choice. Many pet owners choose to use the veterinary practice pharmacy because a lot of advice and assistance is available, including demonstrations on how to administer the treatments.
"Vet-Medic's assertion that pet owners don't know that they can obtain a prescription from their veterinary surgeon is also false. Over 50% of UK practices are registered under the RCVS Practice Standards Scheme. One of the conditions of the scheme is that a notice must be displayed in the waiting room informing clients that prescriptions are available on request, the price of a prescription, and the price list of the top ten medicines that the practice has dispensed in the last three month period.
"It's important to remember that under the law veterinary practices are not allowed to fix the price of medicines. As they are independent businesses this means that it is up to each practice to charge according to their own circumstances to cover their individual overheads."
Idexx says the new test is proven to identify kidney disease earlier than creatinine1–3, enabling veterinary surgeons to intervene earlier and have a greater impact on patients' health outcomes and quality of life.
The Catalyst SDMA Test was first launched at the company's reference laboratories in 2015, since when Idexx says it has run more than 14 million SDMA patient tests, creating the world's largest database on kidney disease in dogs and cats.
The test was then launched to veterinary practices in the USA and Canada last December, where Idexx says it has now been used by thousands of practices.
Jonathan Ayers, Chairman and Chief Executive Officer of Idexx Laboratories said: "We've seen great enthusiasm for the ability to run SDMA as part of the routine chemistry panel at the point of care, and the North American launch has exceeded our expectations.
"The Idexx SDMA Test represents one of the most significant diagnostic innovations in veterinary medicine in the last 30 years. We're thrilled to bring this essential element of the chemistry panel to our point of care Idexx VetLab suite, allowing veterinarians to utilize the benefits of SDMA immediately during the pet's appointment."
Idexx has also signed an agreement to collaborate with Yale University to explore the test's applications in human health. As a result of the partnership, the SDMA Test has been validated for accuracy in measuring SDMA in human blood samples and the results presented at the 2017 annual meeting of the American Society of Nephrology last November by Yale and IDEXX researchers.
Jonathan added: "SDMA has tremendous potential benefit in human applications as well. And with the Idexx test technology now validated to be able to run on commercial chemistry systems that routinely produce chemistry results in human reference laboratories, we have greater reason to explore the clinical value of this incredible biomarker in human applications. We are excited and grateful for our partnership with Yale University."
Idexx says SDMA is now the subject of more than 30 ongoing research collaborations and has been incorporated into the veterinary profession's International Renal Interest Society (IRIS) kidney disease staging guidelines.
For more information about the IDEXX Catalyst SDMA Test, visit www.idexx.eu/sdma.
The hearing proceeded in Ms Kay’s absence as she failed to attend. The Committee heard a number of charges relating to her practising while under the influence of alcohol, breaching undertakings to the College to abstain completely from alcohol, alleged serious clinical failings in relation to the treatment of two dogs, Izzy and Alfie, and making disparaging remarks to a client about other veterinary surgeons (the complete list of charges can be found on the College’s website: www.rcvs.org.uk/concerns/disciplinary-hearings/).
In relation to the first charge, (that in September 2016, while a locum veterinary surgeon at Haven Veterinary Surgeons Group, Great Yarmouth, she was under the influence of alcohol), the Committee heard from a veterinary nurse at the practice who told how on different occasions Miss Kay had appeared to need more assistance than expected, was overly friendly in speaking to clients, was unable to prepare a syringe correctly, and finally, on 14 September 2016, was found asleep in the car with an open can of alcohol by her feet. The Committee also heard from a number of other witnesses from the Haven Veterinary Surgeons Group who also provided evidence of Ms Kay’s behaviour on the day in question. Following deliberations, the Committee found the first charge to be proved.
The second charge related to the breaching of undertakings which Ms Kay had given to the College to the effect that she would abstain completely from alcohol. When samples were taken on 3 August 2017, however, it was found that she had been consuming alcohol in the recent past. The Committee was therefore satisfied that the second charge was proved.
The Committee then turned to the third charge, that in March 2017 Ms Kay had displayed a number of clinical failings when performing surgery on a cocker spaniel, Izzy, belonging to Mrs Debbie Coe. The Committee found the majority of the charges proved, amongst others that she failed to obtain informed consent for surgery, performed surgery in her own home when it was not registered as a veterinary practice and it was not possible to ensure sterility, and that she failed to provide suitable post-operative analgesia to Izzy.
The College then turned to the fourth charge, which concerned her treatment of Mrs Coe’s other dog, Alfie, a Miniature Schnauzer. The charge was that in March 2017, Ms Kay euthanased Alfie in an inappropriate manner, and used a controlled drug without having a registered veterinary premise from which to dispense it. After hearing from an expert witness the Committee found the charges proved.
Finally, the Committee heard evidence relating to the fifth charge, namely that in or around July 2016, Ms Kay made disparaging remarks to Mrs Coe about other veterinary surgeons who had treated Alfie, and that between 17 March and 31 March 2017 she had sent inappropriate texts and voicemail messages to Mrs Coe about the treatment of her dogs and payments owed in relation to this. The Committee thought there was not enough evidence in relation to the voicemails, but found the remainder of the charge proved.
Taking all into account, the Committee found that Ms Kay’s conduct had fallen far short of the standard expected of a member of the veterinary profession and concluded that her conduct clearly amounts to disgraceful conduct in a professional respect.
Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considered that the only appropriate sanction is that of removal from the Register. Such a sanction is required to protect animals and to send a clear message to the Respondent, and to all veterinary surgeons, of the unacceptability of the conduct identified in this case. Such conduct undermines public confidence in the profession and fails to uphold proper standards of conduct and behaviour.
"Accordingly, the Committee has decided that removal from the Register is the only appropriate and proportionate sanction in this case."
Ms Kay has 28 days from being informed about the Disciplinary Committee’s decision to make an appeal to the Privy Council.
An Oxford woman has launched Veterinary Thermal Imaging Ltd, a company which claims to be the first in the UK to use thermal imaging to help identify and monitor injury and illness in domestic pets.
Helen Morrell, 34, uses an FLIR infrared camera to detect physiological changes in animals. She says the technique is traditionally only used in top competition and racing stables, and can highlight health problems, including tendon, joint and nerve damage, which would otherwise be undetectable without invasive and expensive procedures such as x-rays and MRI scans.
Helen said: "I became interested in thermal imaging after being made redundant from my job in financial services. I'd studied Animal Science at Newcastle University when I was younger and I viewed the redundancy as the perfect opportunity to return to the industry.
"I realised that there were only a few people in the country who offer thermal imaging, and then only to horses. It's a really emerging technique that has huge potential and is already widely used in the US across all animals, including domestic, livestock, zoo and wildlife. It seemed that there was a huge gap in the market in this country."
Helen contacted leading experts in the US and became the first British woman to be accepted onto the thermal imaging course at Florida University. She said: "I knew I wanted to use the technique on domestic pets and the experts in the field were all in America. It made sense to me to get the training there and make sure I was at the top of my game."
Helen says she is currently working with a three-year-old terrier called Jack who is suffering from muscular atrophy caused by a locking patella. Although the thermal imaging didn't diagnose the problem, she says it is allowing the monitoring of his treatment and providing an objective assessment of the muscles affected by the injury.
The chewable, prescription-only tablet contains sarolaner, which kills fleas and ticks; moxidectin, for the prevention of heartworm, lungworm disease and for the treatment of some intestinal worms; and pyrantel embonate, for the treatment of gastrointestinal nematodes (hookworms and roundworms).
Professor Tim Geary, BSc PhD, Professor Emeritus, Institute of Parasitology, McGill University, Canada, and Professor, School of Biological Sciences, Queen’s University, Belfast, a consultant to Zoetis, said: “Serious diseases that are preventable and of increasing prevalence threaten dogs in Canada and Europe. Simparica Trio today offers a better solution to preventing and controlling these parasites against the concern of their increasing prevalence."
Rob Kelly, President, International Operations at Zoetis said: "With Simparica Trio, we bring to market an advanced parasiticide solution, helping to deliver improved client satisfaction and patient protection.
"Thanks to its broad spectrum, Simparica Trio helps veterinarians and dog owners provide more complete parasite coverage with a single-monthly chewable tablet. The broad spectrum of Simparica Trio minimises the potential risk of parasite protection gaps."
Simparica Trio is indicated for dogs from at least eight weeks of age and 1.25 kg and will be available in six tablet strengths for dogs of all sizes.
For more information about Simparica Trio and full prescribing information, visit www.zoetis.com.
In the study1, records from a large commercial diagnostic laboratory were searched for canine skin masses submitted for histopathology from dogs aged between 0-12 months from practices based in the UK and Europe.
For each case, data on the breed, age and sex of the dog, the body location of the sample, and the diagnosis made by the original reporting histopathologist were recorded.
For the purposes of the study, masses were included which were cystic, hyperplastic or neoplastic, but not inflammatory.
Submissions of samples from the eyes, anal glands and nails were excluded and only MCTs submissions that were cutaneous were included.
Risk factor analysis using multivariable binary logistic regression modelling was carried out for skin masses with at least 30 submissions.
Professor Ken Smith, corresponding author for the paper, said: “A total of 2553 submissions for a skin mass were included in the study.
"Across all the skin masses, the majority (94.3%) were neoplastic in nature.
"Of the neoplastic lesions, 98.5% were considered benign.
"Almost all of the benign neoplastic lesions were of round cell origin (94.0%), whereas most of the non-neoplastic lesions were derived from the epithelium (93.8%).
“The most common histopathological diagnoses for skin masses were histiocytoma (86.6%), papilloma (3.5%), dermoid cyst (3.3%), follicular cyst (1.7%) and MCT (1.4%).
"Multivariable analysis revealed that Labrador retrievers, Boxers and Golden retrievers had reduced odds of histiocytoma compared to crossbreed dogs.
"Male neutered dogs had lower odds of dermoid cyst compared with female entire animals.
"Dogs aged 9 to 12 months had significantly higher odds of follicular cyst compared with dogs aged under 6 months, whilst dogs aged over 6 months showed significantly higher odds of MCT than dogs under 6 months of age.”
Nicola Di Girolamo, Editor of JSAP, said: “Retrospective studies that include a large number of cases such as this one are an invaluable resource for clinicians working in any setting.
"The findings of this study corroborate those of previous research, suggesting that a skin mass in a young dog is very likely to be a histiocytoma.
"However, the risk factor analysis in this paper identified a number of different predilections to those previously recognised, indicating a need for continued research in this area.”
The full article can be found in the January issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13418
According to the company, stock is now at normal levels in all the major wholesalers. Laura Jenkins, Companion Animal Marketing Manager at the company added: "IsoFlo is now with veterinary customers and we have a full schedule of deliveries for 2019.
"With restocking underway and ample stock awaiting dispatch, plus enough to re-establish safety stock levels shortly, it is good to know practices will be returning to IsoFlo.
"As our teams work to get IsoFlo to you if you have any questions please do get in touch with your local Account Managers.
"We appreciate other suppliers might be sharing information on their stock and we want to reassure our customers of the immediate availability of IsoFlo and once again I would like to extend thanks to the extended team of associations, veterinary surgeons and regulatory bodies who have helped to find other solutions over the two months."
Dexafast is an injectable corticosteroid with potent, medium-acting, anti-inflammatory activity, indicated for the treatment of a range of inflammatory and allergic conditions in both small and large animal clinical practice.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Dexafast 2mg/ml is an excellent addition to our range. This formulation of dexamethasone is used across many species on a daily basis, and Dexafast 2mg/ml gives vets a high-quality presentation of a staple medicine."
Dexafast is available in a 50ml bottle.
For further information, contact your local Forte Territory Manager, visit: https://www.fortehealthcare.ie/product/dexafast-uk-only, or email: enquiries@fortehealthcare.com.
The Disciplinary Committee heard three charges against Dr Dhami, relating to events which took place while he was in practice at Vets4Pets in Market Harborough, Leicestershire.
The first charge against him was that, in November 2017, he used excessive force in kicking and stamping on a Staffordshire Bull Terrier he was treating.
The second charge was that, between in October and November 2017, he failed to pay adequate regard to the welfare of a Jack Russell in his care by leaving it in a sink without adequate reason and for an excessive period of time.
The third charge was that, between April and March 2018, he failed to have adequate regard to the welfare of a six-to-eight week old kitten, including providing bedding and warmth.
At the outset of the hearing Dr Dhami admitted to lightly kicking the dog, but denied forcefully kicking it and also denied that he had stamped on the dog, as well as denying the other two charges against him.
In considering the circumstances of the first charge, the Committee heard evidence from two of Dr Dhami’s colleagues stating that the dog had bitten him whilst he was cleaning its ears and, following this, he took the dog out of the consulting room, closed the door and whilst holding the dog’s lead then proceeded to kick her twice, knocking her along the floor both times, and then finally stamp on her when she was prone.
Dr Dhami disputed his colleagues' version of events and stated that he had only delivered two light kicks to the dog’s rump, that neither of these had made her fall to the floor and also denied in categorical terms that he stamped on the animal. Furthermore, he also denied the second and third charges against him.
In considering the evidence as to whether Dr Dhami kicked and stamped on the dog, the Disciplinary Committee found the evidence of his two colleagues to be credible and reliable, and so found all aspects of the charge proven.
Ian Green, chairing the Committee and speaking on its behalf, said: "For the avoidance of doubt, the Committee finds that the admitted kicks administered to [the animal] by the respondent were of significant force. The Committee rejects the respondent’s assertion that the admitted kicks amounted to mere taps on the backside. The Committee finds that the ‘stamping’ was also of significant force."
In regards to the second and third charges, the Committee was not satisfied that the charges had been proven by the evidence it heard and therefore dismissed them both.
Having found all parts of the first charge proven, the Committee then went on to consider whether or not Dr Dhami’s conduct amounted to serious professional misconduct, something that Dr Dhami, following the Committee’s decision on the facts, through his counsel, had admitted.
The Committee identified a number of aggravating factors, including the real risk of physical harm to the animal and the deliberate nature Dr Dhami’s conduct against the animal, committed in anger.
In mitigation, the Committee accepted that this was an isolated incident and that Dr Dhami had been bitten and was in pain. The Committee therefore found that Dr Dhami’s admission of serious professional misconduct was ‘properly and prudently made’.
The Committee then considered what sanction to impose on Dr Dhami. In doing so it took into account some of the written testimonials and character witnesses called on behalf of Dr Dhami. The Committee was also satisfied that Dr Dhami had had a hitherto long and unblemished career, that he had apologised to colleagues immediately after the incident and that, since the events, he had continued to work as a veterinary surgeon without any problems.
In relation to insight about the event, the Committee accepted Dr Dhami had provided some evidence of reflection, in that he admitted kicking the dog and accepted that this conduct, once found proven, amounted to serious professional misconduct.
The Committee decided that suspending Dr Dhami from the Register for four months would be the most proportionate sanction.
Ian Green concluded: "Having regard to all the matters urged by way of mitigation, and having taken into account all the evidence that it has heard, the Committee is satisfied that a period of suspension is sufficient in this case to protect the welfare of animals, maintain public confidence and to declare and uphold proper standards of conduct."
Dr Dhami has 28 days from being informed of the outcome of the hearing in which to make an appeal to the Privy Council.